Clinical Trial Update: Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating carfilzomib with pegylated liposomal doxorubicin and dexamethasone in relapsed or refractory multiple myeloma has completed with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Pegylated liposomal doxorubicin hydrochloride (pegylated liposomal doxorubicin)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-04-08